![Endocrinology Advisor](https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/002/515/normal/Screen_Shot_2016-09-09_at_13.24.48.png?1473423901)
Progression of Bone Erosion Slows With Addition of Denosumab to DMARDs in RA
Endocrinology Advisor,
Researchers studied the effect of denosumab on bone microarchitecture, using HR-pQCT, in patients with rheumatoid arthritis.
Researchers studied the effect of denosumab on bone microarchitecture, using HR-pQCT, in patients with rheumatoid arthritis.
The addition of denosumab to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) may inhibit the…